A leading pharmaceutical company is making strategic moves in the diabetes treatment market. The organisation has set its sights on expanding its therapeutic portfolio through a significant acquisition of three anti-diabetes brands from a prominent international pharmaceutical manufacturer. This strategic purchase represents a calculated effort to strengthen the company’s position in the metabolic health segment. … Continue reading Pharma stock jumps 3% after company plans to acquire 3 anti diabetes brands